SCHEMBL17014137

SCHEMBL17014137

Cc1ccc(OCc2ccnc(Cl)c2)c2ccccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.41
LOX P28300 1/20 0.41
LOXL3 P58215 1/20 0.41
LOXL2 Q9Y4K0 1/20 0.41
GRM5 P41594 2/20 0.41
MRGPRX4 Q96LA9 2/20 0.40
MGLL Q99685 1/20 0.39
GPR84 Q9NQS5 1/20 0.39
PLAU P00749 1/20 0.37
PLAT P00750 1/20 0.37
MAPT P10636 3/20 0.36
LMNA P02545 2/20 0.36
HTT P42858 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CYP1A2 P05177 1/20 0.36
PTK6 Q13882 1/20 0.35
NPC1 O15118 2/20 0.35
F2 P00734 1/20 0.35
ENPP2 Q13822 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17014132 0.86 MRGPRX4 (0.42) GRM5MRGPRX4PLAUPLATMAPT
SCHEMBL17014135 0.83 NOS3 (0.45) MRGPRX4PLAUPLATMAPTCYP1A2
SCHEMBL18567053 0.81 ABCB1 (0.48) MRGPRX4PLAUPLATMAPTLMNA
SCHEMBL28566745 0.79 MGLL (0.43) RECQLLOXLOXL3LOXL2GRM5
SCHEMBL17004782 0.79 MAPK14 (0.47) MRGPRX4MGLLPTK6
SCHEMBL17008483 0.78 KMT2A (0.46) GRM5MGLLMAPTLMNAHTT
SCHEMBL31086622 0.78 KMT2A (0.46) GRM5MGLLMAPTLMNAHTT
SCHEMBL9609810 0.77 CYP1A2 (0.38) MAPTLMNAHTTCYP1A2CYP2C19
SCHEMBL18567054 0.75 LRRK2 (0.41) MRGPRX4LMNAHTTSMN1; SMN2ALDH1A1
SCHEMBL18546338 0.75 MRGPRX4 (0.44) RECQLMRGPRX4MGLLMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180118719-A1 PYRAZOLYL UREAS AS KINASE INHIBITORS RESPIVERT LIMITED (GB) 2018-05-03 US disclosed
US-9884845-B2 Pyrazolyl-ureas as kinase inhibitors RESPIVERT LIMITED (GB) 2018-02-06 US disclosed
US-20170182039-A1 INHIBITOR OF p38 MAP KINASE TOPIVERT PHARMA LTD. (GB) 2017-06-29 US disclosed
US-9624196-B2 Inhibitor of p38 MAP kinase RESPIVERT LTD. (GB) 2017-04-18 US disclosed
US-20170057945-A1 NOVEL COMPOUNDS RESPIVERT LIMITED (GB) 2017-03-02 US disclosed
US-20160368896-A1 INHIBITOR OF p38 MAP KINASE RESPIVERT LIMITED (GB) 2016-12-22 US disclosed
US-9447076-B2 Inhibitor of p38 map kinase RESPIVERT LTD. (GB) 2016-09-20 US disclosed
US-20150232450-A1 INHIBITOR OF p38 MAP KINASE RESPIVERT LIMITED (GB) 2015-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180118719-A1 PYRAZOLYL UREAS AS KINASE INHIBITORS MAP3K1, MAPK1, MAP3K7 RECQL 3950/4885LOX 1469/4885LOXL3 2444/4885
US-20170182039-A1 INHIBITOR OF p38 MAP KINASE MAPK1, MAPKAPK2, MAP3K1 RECQL 4441/4885LOX 753/4885LOXL3 2669/4885
US-20160368896-A1 INHIBITOR OF p38 MAP KINASE MAPK1, MAPK4, MAPK8 RECQL 3266/4885LOX 729/4885LOXL3 2043/4885
US-20170057945-A1 NOVEL COMPOUNDS MAPK1, MAPK6, MAPKAPK2 RECQL 4403/4885LOX 629/4885LOXL3 857/4885
US-20150232450-A1 INHIBITOR OF p38 MAP KINASE MAPK1, MAPKAPK2, MAPK10 RECQL 4497/4885LOX 1436/4885LOXL3 2610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.